 |
answer text |
<p>The Government is committed to supporting rapid patient access to effective new
medicines in a way that is fair to all parties and represents value to the National
Health Service. The National Institute for Health and Care Excellence (NICE) plays
an important role in supporting patient access to effective new medicines and is able
to recommend most new medicines for use in the NHS. Where there is too much clinical
uncertainty for NICE to be able to recommend routine funding, it is able to recommend
medicines for use through the Cancer Drugs Fund or Innovative Medicines Fund which
make promising medicines available to patients while further real-world evidence is
collected to inform a final NICE recommendation.</p><p>NICE is responsible for the
methods and processes it uses in the evaluation of new medicines and the changes that
it has recently made to its evaluation processes will enable it to produce faster
guidance on simpler, low-risk treatments. NICE and NHS England are exploring options
for rapid entry to managed access (REMA) that build on the experience of the Cancer
Drugs Fund and Innovative Medicines Fund to support managed access to medicines. NICE
has not yet made any changes to its health technology evaluation manual related to
REMA.</p>
|
|
